Merck MRK

Merck & Co. is experiencing significant financial success, with a 50% revenue increase in Q1 2022 driven by $3.2 billion in sales from its COVID-19 antiviral drug, Lagevrio. The company is simultaneously implementing a major restructuring plan aimed at achieving $900 million in savings by 2023. In addition to strong sales in key treatments like Keytruda, Merck is advancing a $1 billion acquisition of Seagen to bolster its cancer portfolio and has announced collaborations with major partners to enhance its drug pipeline. Recently, Merck raised its dividend and continues to attract investment interest as analysts remain optimistic about its growth prospects amidst ongoing drug development efforts.